



(51) International Patent Classification:

C07K 14/55 (2006.01) A61K 38/20 (2006.01)
A61K 38/03 (2006.01) A61K 47/60 (2017.01)

(21) International Application Number:

PCT/US2021/028054

(22) International Filing Date:

20 April 2021 (20.04.2021)

(25) Filing Language:

English

(26) Publication Language:

English

(30) Priority Data:

63/013,583 22 April 2020 (22.04.2020) US

(71) Applicant: **MERCK SHARP & DOHME CORP.**
[US/US]; 126 East Lincoln Avenue, Rahway, NJ
07065-0907 (US).

(72) Inventors; and

(71) Applicants (for US only): **ABRAHAMS, Cristina**
[US/US]; 310 Utah Avenue, Suite 150, South San Francisco,
CA 94080 (US). **BOWMAN, Edward** [US/US]; 213

E. Grand Avenue, South San Francisco, CA 94080 (US).
LI, Xiaofan [US/US]; 310 Utah Avenue, Suite 150, South
San Francisco, CA 94080 (US). **LIN, Songnian** [US/US];
2000 Galloping Hill Road, Kenilworth, NJ 07033 (US).
SOLIS, Willy [US/US]; 1801 Palm Avenue, San Mateo,
CA 94402 (US). **STAFFORD, Ryan** [US/US]; 812 Peary
Lane, Foster City, CA 94404 (US). **WILLINGHAM, Aaron**
[US/US]; 213 E. Grand Avenue, South San Francisco,
CA 94080 (US). **YAM, Alice** [US/US]; 310 Utah Avenue,
Suite 150, South San Francisco, CA 94080 (US). **YANG,**
Junhao [CN/US]; 310 Utah Avenue, Suite 150, South San
Francisco, CA 94080 (US). **YIN, Gang** [CN/US]; 310 Utah
Avenue, Suite 150, South San Francisco, CA 94080 (US).

(74) Common Representative: **MERCK SHARP & DOHME**
CORP.; 310 Utah Avenue, Suite 150, South San Francisco,
CA 94080 (US).

(81) Designated States (unless otherwise indicated, for every
kind of national protection available): AE, AG, AL, AM,
AO, AT, AU, AZ, BA, BB, BG, BH, BN, BR, BW, BY, BZ,
CA, CH, CL, CN, CO, CR, CU, CZ, DE, DJ, DK, DM, DO,
DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, GT, HN,

(54) Title: HUMAN INTERLEUKIN-2 CONJUGATES BIASED FOR THE INTERLEUKIN-2 RECEPTOR BETA GAMMAc DIMER AND CONJUGATED TO A NONPEPTIDIC, WATER-SOLUBLE POLYMER




FIG. 1

(57) Abstract: Interleukin-2 (IL-2) conjugates comprising at least one or more amino acid substitutions that bias binding to the IL-2 receptor $\beta\gamma_c$ dimer over binding the IL-2 receptor $\alpha\beta\gamma_c$ trimer and a non-natural amino acid at or near the N-terminus conjugated to a water-soluble polymer are described. The IL-2 conjugates are useful for treatment and prevention of cell proliferation and cancer in a patient.

[Continued on next page]

HR, HU, ID, IL, IN, IR, IS, IT, JO, JP, KE, KG, KH, KN,
KP, KR, KW, KZ, LA, LC, LK, LR, LS, LU, LY, MA, MD,
ME, MG, MK, MN, MW, MX, MY, MZ, NA, NG, NI, NO,
NZ, OM, PA, PE, PG, PH, PL, PT, QA, RO, RS, RU, RW,
SA, SC, SD, SE, SG, SK, SL, ST, SV, SY, TH, TJ, TM, TN,
TR, TT, TZ, UA, UG, US, UZ, VC, VN, WS, ZA, ZM, ZW.

(84) Designated States (*unless otherwise indicated, for every kind of regional protection available*): ARIPO (BW, GH, GM, KE, LR, LS, MW, MZ, NA, RW, SD, SL, ST, SZ, TZ, UG, ZM, ZW), Eurasian (AM, AZ, BY, KG, KZ, RU, TJ, TM), European (AL, AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HR, HU, IE, IS, IT, LT, LU, LV, MC, MK, MT, NL, NO, PL, PT, RO, RS, SE, SI, SK, SM, TR), OAPI (BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, KM, ML, MR, NE, SN, TD, TG).

Declarations under Rule 4.17:

- *as to applicant's entitlement to apply for and be granted a patent (Rule 4.17(ii))*
- *as to the applicant's entitlement to claim the priority of the earlier application (Rule 4.17(iii))*

Published:

- *with international search report (Art. 21(3))*
- *before the expiration of the time limit for amending the claims and to be republished in the event of receipt of amendments (Rule 48.2(h))*
- *with sequence listing part of description (Rule 5.2(a))*